Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) were up fractionally on Tuesday after activist investment frim Elliot Advisors again called for a company sale."Portola has no chronic rare-disease exposure, the core of Alexion's focus and know-how, and instead targets a broad patient population in the acute hospital setting," the letter read.